BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 24033704)

  • 1. The Zyxin-related protein thyroid receptor interacting protein 6 (TRIP6) is overexpressed in Ewing's sarcoma and promotes migration, invasion and cell growth.
    Grunewald TG; Willier S; Janik D; Unland R; Reiss C; Prazeres da Costa O; Buch T; Dirksen U; Richter GH; Neff F; Burdach S; Butt E
    Biol Cell; 2013 Nov; 105(11):535-47. PubMed ID: 24033704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TRIP6 promotes tumorigenic capability through regulating FOXC1 in hepatocellular carcinoma.
    Wang F; Zhang B; Xu X; Zhu L; Zhu X
    Pathol Res Pract; 2020 Apr; 216(4):152850. PubMed ID: 32046874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Thyroid Receptor Interacting Protein 6 by MicroRNA-589-5p Inhibits Cell Proliferation, Migration, and Invasion in Endometrial Carcinoma.
    Wang Y; Dong L; Liu Y
    Cancer Biother Radiopharm; 2019 Oct; 34(8):529-536. PubMed ID: 31424277
    [No Abstract]   [Full Text] [Related]  

  • 4. TRIP6 accelerates the proliferation and invasion of cervical cancer by upregulating oncogenic YAP signaling.
    Yang F; Li L; Zhang J; Zhang J; Yang L
    Exp Cell Res; 2020 Nov; 396(1):112248. PubMed ID: 32853630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TTPAL Promotes Colorectal Tumorigenesis by Stabilizing TRIP6 to Activate Wnt/β-Catenin Signaling.
    Gou H; Liang JQ; Zhang L; Chen H; Zhang Y; Li R; Wang X; Ji J; Tong JH; To KF; Sung JJY; Chan FKL; Fang JY; Yu J
    Cancer Res; 2019 Jul; 79(13):3332-3346. PubMed ID: 31018940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing's tumor cells.
    García-Aragoncillo E; Carrillo J; Lalli E; Agra N; Gómez-López G; Pestaña A; Alonso J
    Oncogene; 2008 Oct; 27(46):6034-43. PubMed ID: 18591936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA‑34b promotes proliferation, migration and invasion of Ewing's sarcoma cells by downregulating Notch1.
    Lu Q; Lu M; Li D; Zhang S
    Mol Med Rep; 2018 Oct; 18(4):3577-3588. PubMed ID: 30106161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining the role of TRIP6 in cell physiology and cancer.
    Willier S; Butt E; Richter GH; Burdach S; Grunewald TG
    Biol Cell; 2011 Dec; 103(12):573-91. PubMed ID: 22054418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting of EWS/FLI-1 by RNA interference attenuates the tumor phenotype of Ewing's sarcoma cells in vitro.
    Chansky HA; Barahmand-Pour F; Mei Q; Kahn-Farooqi W; Zielinska-Kwiatkowska A; Blackburn M; Chansky K; Conrad EU; Bruckner JD; Greenlee TK; Yang L
    J Orthop Res; 2004 Jul; 22(4):910-7. PubMed ID: 15183454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The zyxin-related protein TRIP6 interacts with PDZ motifs in the adaptor protein RIL and the protein tyrosine phosphatase PTP-BL.
    Cuppen E; van Ham M; Wansink DG; de Leeuw A; Wieringa B; Hendriks W
    Eur J Cell Biol; 2000 Apr; 79(4):283-93. PubMed ID: 10826496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EWS-FLI1-mediated tenascin-C expression promotes tumour progression by targeting MALAT1 through integrin α5β1-mediated YAP activation in Ewing sarcoma.
    He S; Huang Q; Hu J; Li L; Xiao Y; Yu H; Han Z; Wang T; Zhou W; Wei H; Xiao J
    Br J Cancer; 2019 Nov; 121(11):922-933. PubMed ID: 31649319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of connexin43 expression in Ewing's sarcoma cells favors the development of the primary tumor and the associated bone osteolysis.
    Talbot J; Brion R; Picarda G; Amiaud J; Chesneau J; Bougras G; Stresing V; Tirode F; Heymann D; Redini F; Verrecchia F
    Biochim Biophys Acta; 2013 Apr; 1832(4):553-64. PubMed ID: 23313578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TRIP6 promotes cell proliferation in hepatocellular carcinoma via suppression of FOXO3a.
    Zhao W; Dai Y; Dai T; Xie T; Su X; Li J; Zhou X; Meng K; Zhao X
    Biochem Biophys Res Commun; 2017 Dec; 494(3-4):594-601. PubMed ID: 29080747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The EWS/FLI1 oncogenic protein inhibits expression of the Wnt inhibitor DICKKOPF-1 gene and antagonizes beta-catenin/TCF-mediated transcription.
    Navarro D; Agra N; Pestaña A; Alonso J; González-Sancho JM
    Carcinogenesis; 2010 Mar; 31(3):394-401. PubMed ID: 20019092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma.
    Lin PP; Brody RI; Hamelin AC; Bradner JE; Healey JH; Ladanyi M
    Cancer Res; 1999 Apr; 59(7):1428-32. PubMed ID: 10197607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRIP6 regulates neural stem cell maintenance in the postnatal mammalian subventricular zone.
    Lai YJ; Li MY; Yang CY; Huang KH; Tsai JC; Wang TW
    Dev Dyn; 2014 Sep; 243(9):1130-42. PubMed ID: 25044744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of TRIP6-dependent nasopharyngeal cancer cell migration.
    Fei J; Li J; Shen S; Zhou W
    Tumour Biol; 2013 Aug; 34(4):2329-35. PubMed ID: 23576104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transactivation of cyclin E gene by EWS-Fli1 and antitumor effects of cyclin dependent kinase inhibitor on Ewing's family tumor cells.
    Li X; Tanaka K; Nakatani F; Matsunobu T; Sakimura R; Hanada M; Okada T; Nakamura T; Iwamoto Y
    Int J Cancer; 2005 Sep; 116(3):385-94. PubMed ID: 15818598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein.
    Hahm KB; Cho K; Lee C; Im YH; Chang J; Choi SG; Sorensen PH; Thiele CJ; Kim SJ
    Nat Genet; 1999 Oct; 23(2):222-7. PubMed ID: 10508522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. STEAP1 is associated with the invasive and oxidative stress phenotype of Ewing tumors.
    Grunewald TG; Diebold I; Esposito I; Plehm S; Hauer K; Thiel U; da Silva-Buttkus P; Neff F; Unland R; Müller-Tidow C; Zobywalski C; Lohrig K; Lewandrowski U; Sickmann A; Prazeres da Costa O; Görlach A; Cossarizza A; Butt E; Richter GH; Burdach S
    Mol Cancer Res; 2012 Jan; 10(1):52-65. PubMed ID: 22080479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.